XP 005
Latest Information Update: 16 Jun 2025
At a glance
- Originator Shanghai Xinpu BioTechnology Company
- Class Antineoplastics; Cancer vaccines; Immunoconjugates; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Acute myeloid leukaemia
Most Recent Events
- 30 May 2025 Phase-0 for Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in China (unspecified route) (NCT06980155)
- 30 May 2025 Phase-0 for Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in China (unspecified route) (NCT06980155)